Filing summary
Entity and period mismatch: The request identifies Solana Co and “2021 Q4,” but the supplied filing is Helius Medical Technologies, Inc. (Nasdaq: HSDT), Form 10-K for the fiscal year ended December 31, 2021. This summary reflects the supplied filing, not Solana Co.
Business context and reporting period
Helius is a neurotechnology company whose sole commercial product is the Portable Neuromodulation Stimulator (PoNS), used with supervised therapeutic exercise. At year-end, PoNS was authorized in the U.S. for short-term treatment of gait deficit associated with mild-to-moderate multiple sclerosis (MS) in adults 22 and older; in Canada for specified MS and mild-to-moderate traumatic brain injury (mmTBI) indications; and in Australia for improving balance and gait as an adjunct to exercise. The company was commercializing in Canada and preparing a U.S. launch. The filing reports full-year results, with 2020 as the comparable period.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $0.522 million | $0.661 million |
| Gross profit / gross margin | $0.224 million / 42.9% | $0.273 million / 41.3% |
| Operating expenses | $18.366 million | $14.659 million |
| Operating loss | $18.142 million | $14.386 million |
| Net loss | $18.132 million | $14.130 million |
| Cash used in operations | $13.388 million | $11.738 million |
| Cash at year-end | $11.005 million | $3.331 million |
| Working capital | $9.941 million | $2.261 million |
Product sales were $0.493 million in 2021, down from $0.625 million; the balance of revenue was principally license revenue. The balance sheet reported total liabilities of $2.846 million, including deferred revenue, accrued liabilities and lease liabilities; it lists no borrowings. No interest was paid in either year. The company reported an accumulated deficit of $137.035 million. Basic and diluted loss per share was $7.38 in 2021 versus $11.80 in 2020; weighted-average shares increased to 2.457 million from 1.198 million.
Material changes versus 2020
- Revenue declined about 21%, primarily from lower Canadian PoNS sales, which management attributed to COVID-19 impacts and pricing changes.
- Net loss increased by about $4.0 million. R&D expense rose $1.408 million and selling, general and administrative expense rose $2.462 million, reflecting product development, clinical and professional costs, expanded commercial preparation, personnel and stock-based compensation.
- Operating cash use increased by $1.650 million. Financing provided $21.126 million, mainly through two public offerings, warrant exercises and sales under the Lincoln Park purchase agreement; year-end cash increased by $7.674 million.
- Shares issued and outstanding rose from 1.484 million at year-end 2020 to 3.781 million at year-end 2021, reflecting substantial equity financing and dilution.
Outlook, risks and unusual items
- Management expected U.S. commercial sales to begin in the near term and projected revenue to increase substantially in 2022. It expected expenses to rise with commercialization, manufacturing, clinical trials and staffing. The filing does not provide quantified revenue or earnings guidance.
- Management said existing capital resources were expected to fund operations into the third quarter of 2022, while also stating additional financing would be needed to fund operations beyond the beginning of that quarter. The auditor’s report and management disclosed substantial doubt about the company’s ability to continue as a going concern. Access to up to $15 million under the Lincoln Park facility was conditional and not a committed cash balance.
- Medicare’s planned Innovative Technology coverage pathway was rescinded in November 2021. The company was pursuing reimbursement and had applied for unique HCPCS codes; it expected broad government and commercial payer coverage to take at least 24 months. It anticipated self-pay would be an initial U.S. sales channel.
- PoNS’s U.S. authorization covered MS, not mmTBI. The FDA denied the company’s mmTBI de novo request in 2019, citing insufficient evidence to separate the device’s contribution from physical therapy; further study was contingent on nondilutive funding. A stroke trial was planned for 2022, not yet underway at the filing date.
- COVID-19, reduced clinic capacity in Canada, supplier labor and component shortages, and single-source contract manufacturing had disrupted or threatened sales, product availability and clinical work. Management reported production delays beginning in late 2021.
- Unusual costs included approximately $1.0 million of 2021 stock-based compensation associated with a one-time fully vested option grant to the then-interim CEO. The company also recorded $4.252 million of total stock-based compensation for the year.
- The auditor issued an unqualified opinion on the financial statements but included a going-concern explanatory paragraph. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to attest to internal-control effectiveness.
Key facts investors should verify
- Confirm the intended issuer: the supplied filing is for Helius Medical Technologies, Inc., not Solana Co.
- Check subsequent filings for actual U.S. launch timing, sales, prescriptions, clinic adoption and patient throughput; the filing’s “near term” sales expectation is not a quantified forecast.
- Review subsequent cash burn, financing, equity issuance and runway against the disclosed expectation that funding would be needed around the beginning of Q3 2022.
- Track HCPCS coding, Medicare and commercial coverage decisions, reimbursement levels, and the company’s dependence on self-pay patients during the interim.
- Assess manufacturing capacity, supply-chain resolution and product availability, alongside the progress and funding of planned clinical studies and regulatory applications.